Seeking Alpha
 

Baxter International Inc (BAX)

- NYSE
Show Summaries  |  Hide Summaries
  • Tue, May 12, 11:31 AM
  • Wed, Mar. 4, 9:27 AM
  • Dec. 15, 2014, 10:48 AM
  • Dec. 1, 2014, 8:10 AM
  • Jul. 30, 2014, 9:35 AM
  • Jul. 9, 2014, 9:16 AM
    | Comment!
  • Sep. 6, 2013, 12:29 PM
  • Aug. 13, 2013, 8:00 AM
  • Jul. 11, 2013, 7:24 AM
    EU antitrust regulators are reportedly set to authorize Baxter's (BAX) $4B acquisition of Sweden's Gambro after the U.S. firm offered to sell its global continuous renal replacement therapy operations, which account for approximately 2% of its renal product sales. Baxter has made the same offer to authorities in Australia and New Zealand. Acquisition of Gambro would turn Baxter into the second-largest manufacturer in the dialysis market. The EU is due to decide on the deal on July 22.
    | Comment!
  • Dec. 4, 2012, 9:07 AM
    More on Baxter (BAX) / Gambro deal: the acquisition, Baxter's largest ever, combines the second and third largest manufacturers of dialysis equipment, so it could arouse antitrust concerns. Baxter expects synergies of $300M a year by 2017, but says the deal will cut adjusted EPS by $0.10-$0.15 next year and be neutral or add to earnings in 2014, and then add to profit after that. (Webcast) (PR)
    | Comment!
  • Dec. 4, 2012, 7:13 AM
    As tipped about 10 days ago, Baxter International (BAX) inks an agreement to buy Sweden's Gambro for $4B. The acquisition should give Baxter a more complete line of dialysis products. Baxter shares leaped around 5% on the day of the initial leak of the talks, but have since given up those gains. (PR)
    | Comment!
  • Nov. 23, 2012, 10:35 AM
    Baxter International (BAX +1.4%) is in talks on a deal to buy Swedish medical-equipment maker Gambro for roughly $4B. Though still in its early stages, the companies are aiming to complete a deal within the next two to three weeks.
    | Comment!
  • Dec. 13, 2011, 8:31 AM
    Diversified medical products giant Baxter (BAX) announces it's acquiring surgical device maker Synovis (SYNO) for $28/share, or $260M after adjusting for net cash. The price represents a 52% premium to Synovis' Monday close. Baxter expects the deal, which is expected to close in Q1, will be dilutive to its 2012 EPS by $0.04, but will be neutral to 2013 EPS, and accretive afterwards.
    | Comment!
  • Apr. 18, 2011, 8:42 AM
    Baxter (BAX) will acquire privately-held Prism Pharma for $338M, $168M of that based on milestones. Prism's NEXTERONE portfolio includes the only ready-to-use premixed IV bag formulations, as well as vials and a pre-filled syringe. (PR)
    | Comment!
Visit Seeking Alpha's
BAX vs. ETF Alternatives
Company Description
Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.